Shore Capital Reiterates Hold Rating for GlaxoSmithKline plc (GSK)
GlaxoSmithKline plc (LON:GSK)‘s stock had its “hold” rating reiterated by equities researchers at Shore Capital in a report issued on Friday, June 2nd, Marketbeat reports.
GSK has been the subject of a number of other research reports. Jefferies Group LLC raised their price objective on GlaxoSmithKline plc from GBX 1,780 ($22.52) to GBX 1,800 ($22.77) and gave the company a “buy” rating in a research report on Friday, February 17th. Beaufort Securities restated a “buy” rating and set a GBX 1,750 ($22.14) price objective on shares of GlaxoSmithKline plc in a research report on Thursday, February 16th. HSBC Holdings plc restated a “buy” rating and set a GBX 1,970 ($24.92) price objective on shares of GlaxoSmithKline plc in a research report on Wednesday, March 15th. BNP Paribas restated an “underperform” rating and set a GBX 1,520 ($19.23) price objective on shares of GlaxoSmithKline plc in a research report on Monday, February 27th. Finally, Goldman Sachs Group, Inc. (The) set a GBX 1,850 ($23.40) price objective on GlaxoSmithKline plc and gave the company a “buy” rating in a research report on Wednesday, February 15th. Four equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the stock. GlaxoSmithKline plc presently has an average rating of “Hold” and a consensus price target of GBX 1,745.17 ($22.08).
GlaxoSmithKline plc (LON:GSK) traded up 0.06% during midday trading on Friday, reaching GBX 1685.00. The company had a trading volume of 19,969,256 shares. The company has a 50-day moving average price of GBX 1,647.07 and a 200-day moving average price of GBX 1,604.10. GlaxoSmithKline plc has a one year low of GBX 1,363.00 and a one year high of GBX 1,745.56. The stock’s market capitalization is GBX 82.33 billion.
The business also recently declared a dividend, which will be paid on Thursday, July 13th. Stockholders of record on Thursday, May 11th will be paid a dividend of GBX 19 ($0.24) per share. This represents a dividend yield of 1.21%. The ex-dividend date of this dividend is Thursday, May 11th.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/06/16/glaxosmithkline-plc-gsk-receives-hold-rating-from-shore-capital-updated-updated.html.
In other GlaxoSmithKline plc news, insider Vivienne Cox acquired 335 shares of GlaxoSmithKline plc stock in a transaction that occurred on Wednesday, April 26th. The stock was bought at an average price of GBX 1,583 ($20.03) per share, with a total value of £5,303.05 ($6,708.48). Also, insider Emma Walmsley acquired 83 shares of GlaxoSmithKline plc stock in a transaction that occurred on Tuesday, April 18th. The stock was acquired at an average cost of GBX 1,647 ($20.83) per share, with a total value of £1,367.01 ($1,729.30). Insiders have bought 662 shares of company stock valued at $1,067,188 in the last ninety days.
About GlaxoSmithKline plc
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Stock Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related stocks with our FREE daily email newsletter.